A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

NCT02981472 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombosis

Interventions

DRUG: Apixaban
DRUG: Vitamin K Antagonist (VKA)
DRUG: Low Molecular Weight Heparin (LMWH)

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]
[object Object]